Clinical trial
Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer
NCT00006381 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00006381 |
|---|---|
| Title | Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer |
| Official title | Phase II Study of Celecoxib in HER-2/Neu Overexpressing Metastatic Breast Cancer Patients Who Have Failed Recombinant Humanized Anti-p 185HER Monoclonal Antibody Trastuzumab (HERCEPTIN) |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, celecoxib |
| Start date | Jun 1, 2000 |
| Completion | Feb 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: